Avery TL, Rehg JE, Lumm WC, et al. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res.1989:4972- 4978.
5.
Beutler E., Piro LD, Saven A., et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma. 1991;5:1-8.
6.
Orr RM, Talbot DC, Aherne GW, et al. 2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines. Clin Cancer Res.1995;1:391-398.
7.
Carson DA, Wasson DB, Taetle R., et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood.1983 ;62:737-743.
8.
Piro LD 2-Chlorodeoxyadenosine: drug development priorities. J Clin Oncol.1992;10:1507-1510.
9.
Carrera CJ, Terai C., Piro L., et al. 2-CdA chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J Purine Pyrimidine Res.1991;2(Suppl 1):38.
10.
Seto S., Carrera CJ, Kubota M., et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest.1985;75:377-383.
11.
Robertson LE , Chubb S., Meyn R., et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine . Blood.1993;81:143-150.
12.
Kawasaki H. , Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine . Blood.1993;81:597-601.
13.
Piro LD2-Chlorodeoxyadenosine treatment of lymphoid malignancies. Blood.1992;79:843-845.
14.
Carrera CJ, Yamanaka H., Piro LD, et al. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv Exp Med Biol . 1989:253b.
15.
Petzer AL, Bilgeri R., Zilian U., et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood.1991;78:2583-2587.
16.
Hutton JJ, von Hoff DDCytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay . Cancer Drug Deliv.1986; 3:115-122.
17.
Liliemark J. , Albertioni F., Hassan M., et al. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration . J Clin Oncol.1992 ;10:1514 -1518.
18.
Saven A., Cheung WK, Smith I., et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol.1996;14:978-983.
19.
Albertioni F., Juliusson G., Liliemark J.On the bioavailability of 2-chlorodeoxyadenosine (2-CdA): the influence of food and omeprazole. Eur J Clin Pharmacol.1993;44:579-582.
20.
Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2-deoxyadenosine . Proc Natl Acad Sci USA. 1992;89:2970 -2974.
21.
Liliemark J. , Juliusson G.On the pharmacokinetics of 2-chloro-2'deoxyadenosine in humans. Cancer Res.1991;51:5570-5572.
22.
Liliemark J. , Juliusson G.On the pharmacokinetics of 2-chloro-2'deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Blood. 1992; 80(Suppl 1):471a.
23.
Liliemark J. , Petterson B., Juliusson G.The relationship between plasma 2-chlorodeoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous IV infusion in patients with chronic lymphocytic leukemia. Blood. 1991;78(Suppl):33a.
24.
LiliemarkJ. , Juliusson G.Cellular pharmacokinetics of 2-chloro-2'deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clinical Cancer Res.1995;1:385-390.
25.
Marks RS, Richardson RL, Reid JM, et al. A phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors. Proc Am Soc Clin Oncol.1994;13:155. Abstract 416.
26.
Estey EH, Kurzrock R., Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-ODA). Blood. 1992;79: 882-887.
27.
Weiss GR, Kuhn JG, Smith LS, et al. A phase I trial and pharmacokinetic study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer ChemoPharmacol.1995;35(5):397-402.
28.
Santana VM, Mirro J.Jr, Harwood FC, et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol.1991;9:416-422.
29.
Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res.1994;54:1235-1239.
30.
Spielberger RT, O'Brien S., Ratain MJ, et al. Phase I study of 2-chlorodeoxyadenosine in hematologic malignancies. Blood.1992;80:1831a.
31.
Kornblau SM , Gandhi V., Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia.1996;10:1563-1569.
32.
Larson RA, Mick R., Spielberger RT, et al. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol.1996;14:188- 195.
33.
Tefferi A., Witzig TE, Reid JM, et al. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol.1994;12:569- 574.
34.
Saven A., Kawasaki H., Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies . J Clin Oncol.1993;11:671- 678.
35.
Kobayashi K. , Vogelzang NJ, O'Brien S., et al. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer.1994;74:168-173.
36.
Faguet GBChronic lymphocytic leukemia: an updated review. J Clin Oncol.1994;12:1974-1990.
37.
Piro LD, Carrera CJ, Beutler E., et al. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood.1988 ;72:1069-1073.
38.
Juliusson G. , Liliemark J.High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol.1993;11:679- 689.
39.
Saven A., Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph.1991;5(Suppl):133-138.
40.
Tallman MS, Hakimian D., Zanzig C., et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol.1995;13:983-988.
41.
Juliusson G. , Elmhorn-Rosenborg A., Liliemark J.Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med.1992 ;327:1056-1061.
42.
Delannoy A. , Hanique G., Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine . N Engl J Med.1993;328:812. Letter.
43.
Saven A., Lemon RH, Piro LD 2- Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med.1993 ;328:812-813. Letter.
44.
O'Brien S., Kantarjian H., Estey E., et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med.1994; 330:319-322.
45.
Saven A., Lemon RH, Kosty M., et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol.1995;13:570-574.
46.
Juliusson G. , Christiansen I., Hansen MM, et al. Oral cladribine as primary therapy for symptomatic chronic lymphocytic leukemia (CLL). J Clin Oncol.1996;14:2160 - 2166.
47.
Dellanoy A. , Martiat P., Gala JL, et al. 2-Chlorodeoxyadenosine (CdA) for patients with B-cell chronic lymphocytic leukemia. Leukemia. 1995;9:1130-1135.
48.
Saven A., Piro LDTreatment of hairy cell leukemia. Blood.1992 ;79:1111-1120.
49.
Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med.1990;322:1117-1121.
50.
Piro LD, Saven A., Ellison D., et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol.1992;11:846a.
51.
Estey EH, Kurzrock R., Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood.1992;79: 882-887.
52.
Lauria F., Benfenati D., Raspadori D., et al. 2-Chlorodeoxyadenosine in the treatment of patients with hairy cell leukemia. Blood.1991;79(Suppl 1):34a.
53.
Juliusson G. , Liliemark J.Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood.1992;79:888-894.
54.
Tallman MS, Hakimian D., Variakojis D., et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood.1992;80: 2203-2209.
55.
Tallman MS, Hakimian D., Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood.1996;88:1954- 1959.
56.
Saven A., Piro LDComplete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Ann Intern Med.1993;119:278-283.
57.
Cheson BDInfectious and immunosuppressive complications of purine analog therapy . J Clin Oncol.1995;13:2431-2448.
58.
Juliusson G. , Heldal D., Hippe E., et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol.1995;13:989-995.
59.
Hakimian D. , Tallman MS, Kiley C., et al. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood.1993;82: 1798-1802.
60.
Wheaton S., Tallman MS, Hakimian D., et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood.1996187:1556-1560.
61.
Cancer Facts and Figures. Atlanta, Ga: American Cancer Society; 1997.
62.
Kay AC, Saven A., Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol.1992;10:371-377.
63.
Hoffman M., Tallman MS, Hakimian D., et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol.1994;12:788-792.
64.
Hickish T., Serafinowski P., Cunningham D., et al. 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer.1993;67:139-143.
65.
Khan A., Schiller G., Levine A., et al. 2-Chloro-2'-deoxyadenosine (2-CdA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol.1994;13:386. Abstract 1315.
66.
Saven A., Lee T., Kosty M., et al. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol.1996;14:2139 -2144.
67.
Saven A., Emanuele S., Kosty M., et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood.1995 ;86:1710-1716.
68.
Canfield V. , Baughman C., Vose J.A phase II trial of 2-chlorodeoxyadenosine (2-CdA) in previously untreated patients (pts) with low grade non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol.1994 ;13:381. Abstract 1292.
69.
Saven A., Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood.1992;80:587-592.
70.
Kuzel TM, Hurria A., Samuelson E., et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood.1996;87:906-911.
71.
O'Brien S., Kurzrock R., Duvic M., et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood.1994;84:733-738.
72.
Santana VM, Mirro J.Jr, Kearns C., et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol.1992;10:364 -370.
73.
Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood.1994 ;84:1237-1242.
74.
Vahdat L., Wong ET, Wile MJ, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood.1994;84:3429-3434.
75.
Van den Neste E., Ferrant A., Delannoy A., et al. 2-Chloro-deoxyadenosine with or without daunorubicin for relapsing or refractory acute myeloblastic leukemia. Blood.1993;82(Suppl 1):503a.
76.
Saven A., Piro LD, Lemon RH, et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer. 1994;73:2953-2963.
77.
Dann EJ, Anastasi J., Larson RAHigh dose cladribine (2CDA) therapy for chronic myelogenous leukemia in blast phase (CML-BP). Blood. 1996;88(Suppl 1):235a.
78.
Dimopoulos MA, Kantarjian H., Estey E., et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med.1993;118:195-198.
79.
Dimopoulos MA, Kantarjian H., Wever D., et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol.1994;12:2694-2698.
80.
Dimopoulos MA, Weber DM, Kantarjian H., et al. 2-Chlorodeoxyadenine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol.1994;5:288-289.
81.
Pless M., Gratwohl A., Fichelli A., et al. 2-Chloro-deoxyadenosine as treatment of severe acute graft versus host disease. Blood.1993; 82(Suppl 1):1667a.
82.
Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis . Lancet. 1994;344:9-13.
83.
Ryba M., Grieb P., Pastuszko M., et al. Successful prevention of neurological deficit in SAH patients with 2-chlorodeoxyadenosine. Acta Neurochir.1993;124:61- 65.
84.
Cheson BD, Vena DA, Foss FM, Sorensen JMNeurotoxicity of purine analogs: a review. J Clin Oncol.1994;12:2216-2228.
85.
Kobayashi K. , Vogelsang NJ, O'Brien SM, et al. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer.1994;74:168-173.
86.
Dann EJ, Gillis S., Polliack A., et al. Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J med.1993;329: 1547-1548.
87.
Cardinale V, ed. Red Book . Montvale, NJ: Medical Economics ; 1996.
